Assignee
CANTEX PHARMACEUTICALS INC
US·6 granted patents·12 pending applications·9 citations·filing 2013–2023
Top patents by PatentIndex Score
18 records- 0188US10052346B2Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoidsCANTEX PHARMACEUTICALS INC·Filed 2016·Granted Aug 21, 2018·4 cites·19 claims
- 0287US11648235B1Treatment of glioblastomaCANTEX PHARMACEUTICALS INC·Filed 2022·Granted May 16, 2023·1 cites·30 claims
- 0380US9271999B2Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2013·Granted Mar 1, 2016·4 cites·22 claims
- 0474US11229664B2Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2019·Granted Jan 25, 2022·0 cites·20 claims
- 0574US2022354882A1Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0671US2022054531A1Treatment of acute myeloid leukemia with hypomethylating agents and 2-o, 3-o desulfated heparinoidsCANTEX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0770US10905661B2Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage formsCANTEX PHARMACEUTICALS INC·Filed 2019·Granted Feb 2, 2021·0 cites·18 claims
- 0867US2024216333A1Treatment of glioblastomaCANTEX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0966US10322096B2Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage formsCANTEX PHARMACEUTICALS INC·Filed 2017·Granted Jun 18, 2019·0 cites·2 claims
- 1066US2019015443A1Treatment of myelodysplastic syndromes with 2-o and, or 3-o desulfated heparinoidsCANTEX PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1164US2020237803A1Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interactionCANTEX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1262US2020397726A1Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage formsCANTEX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1360US2018296590A1Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1454US2016213706A1Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1543US2016287626A1Methods of treating and preventing radiation damageCANTEX PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1641US2017106011A1Methods of treating traumatic brain injury and sequelaeCANTEX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1739US2016243168A1Adoptive cell transfer methodsCANTEX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1831US2017096549A1Multivalent cation formulations of partially desulfated heparinsCANTEX PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CANTEX PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →